BlackRock Amends Cara Therapeutics Stake (13G/A)
Ticker: TVRD · Form: SC 13G/A · Filed: Jan 29, 2024 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | SC 13G/A |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**BlackRock updated its passive stake in Cara Therapeutics as of year-end 2023.**
AI Summary
BlackRock Inc. has filed an amended Schedule 13G/A, indicating a change in its ownership stake in Cara Therapeutics, Inc. as of December 31, 2023. This filing, Amendment No. 9, updates BlackRock's passive investment position in the pharmaceutical company. For investors, this matters because BlackRock is a major institutional investor, and changes in its holdings can signal shifts in its confidence or strategy regarding Cara Therapeutics' future prospects.
Why It Matters
This filing shows BlackRock's updated passive investment in Cara Therapeutics, providing transparency on a significant institutional holder's position.
Risk Assessment
Risk Level: low — This is a routine update from a passive institutional investor and does not indicate any immediate high-risk event.
Analyst Insight
Investors should note BlackRock's continued passive interest in Cara Therapeutics, but this filing alone doesn't suggest a strong buy or sell signal. It's a routine disclosure of an updated institutional holding.
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Cara Therapeutics, Inc. (company) — the subject company whose shares are being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- Amendment No. 9 (number) — the specific amendment number of the filing
FAQ
What type of filing is this document?
This document is an SC 13G/A, which is an amendment to a Schedule 13G filing, as stated in the 'FORM TYPE: SC 13G/A' section and the document title.
Which company is the subject of this filing?
The subject company is Cara Therapeutics, Inc., identified by 'COMPANY CONFORMED NAME: Cara Therapeutics, Inc.' and 'Name of Issuer: CARA THERAPEUTICS INC'.
Who filed this SC 13G/A?
This SC 13G/A was filed by BlackRock Inc., as indicated under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.'.
What was the date of the event that triggered this filing?
The date of the event which requires the filing of this statement was December 31, 2023, as specified under 'Date of Event Which Requires Filing of this Statement'.
What is the CUSIP number for Cara Therapeutics, Inc. common stock?
The CUSIP number for Cara Therapeutics, Inc. Common Stock is 140755109, as listed under 'CUSIP No. 140755109'.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 29, 2024 regarding Cara Therapeutics, Inc. (TVRD).